ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Merck & Co. has agreed to buy the ophthalmology firm EyeBio for $1.3 billion up front and up to $1.7 billion in milestone payments. Once the deal closes, Merck will inherit a trispecific antibody called Restoret, which EyeBio is developing as a treatment for vision loss caused by diabetic macular edema and neovascular age-related macular degeneration. Restoret is in early-stage human trials.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter